Adam Craig became the CEO of CTI BioPharma Corp. (NASDAQ:CTIC) in 2017. This analysis aims first to contrast CEO compensation with other companies that have similar market capitalization. Then we'll look at a snap shot of the business growth. And finally we will reflect on how common stockholders have fared in the last few years, as a secondary measure of performance. This method should give us information to assess how appropriately the company pays the CEO.
Check out our latest analysis for CTI BioPharma
How Does Adam Craig's Compensation Compare With Similar Sized Companies?
According to our data, CTI BioPharma Corp. has a market capitalization of US$74m, and paid its CEO total annual compensation worth US$3.0m over the year to December 2018. While this analysis focuses on total compensation, it's worth noting the salary is lower, valued at US$564k. We note that more than half of the total compensation is not the salary; and performance requirements may apply to this non-salary portion. We examined a group of similar sized companies, with market capitalizations of below US$200m. The median CEO total compensation in that group is US$523k.
It would therefore appear that CTI BioPharma Corp. pays Adam Craig more than the median CEO remuneration at companies of a similar size, in the same market. However, this fact alone doesn't mean the remuneration is too high. A closer look at the performance of the underlying business will give us a better idea about whether the pay is particularly generous.
You can see a visual representation of the CEO compensation at CTI BioPharma, below.
Is CTI BioPharma Corp. Growing?
Over the last three years CTI BioPharma Corp. has grown its earnings per share (EPS) by an average of 58% per year (using a line of best fit). Its revenue is up 38% over last year.
Overall this is a positive result for shareholders, showing that the company has improved in recent years. It's great to see that revenue growth is strong, too. These metrics suggest the business is growing strongly. It could be important to check this free visual depiction of what analysts expect for the future.
Has CTI BioPharma Corp. Been A Good Investment?
With a three year total loss of 73%, CTI BioPharma Corp. would certainly have some dissatisfied shareholders. It therefore might be upsetting for shareholders if the CEO were paid generously.
In Summary...
We compared the total CEO remuneration paid by CTI BioPharma Corp., and compared it to remuneration at a group of similar sized companies. Our data suggests that it pays above the median CEO pay within that group.
However we must not forget that the EPS growth has been very strong over three years. On the other hand returns to investors over the same period have probably disappointed many. Considering the per share profit growth, but keeping in mind the weak returns, we'd need more time to form a view on CEO compensation. If you think CEO compensation levels are interesting you will probably really like this free visualization of insider trading at CTI BioPharma.
Of course, you might find a fantastic investment by looking elsewhere. So take a peek at this free list of interesting companies.
If you spot an error that warrants correction, please contact the editor at editorial-team@simplywallst.com. This article by Simply Wall St is general in nature. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. Simply Wall St has no position in the stocks mentioned.
We aim to bring you long-term focused research analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Thank you for reading.
"corp" - Google News
January 27, 2020 at 07:14PM
https://ift.tt/38GrQZL
Should You Be Pleased About The CEO Pay At CTI BioPharma Corp.'s (NASDAQ:CTIC) - Yahoo Finance
"corp" - Google News
https://ift.tt/2RhVoHj
Shoes Man Tutorial
Pos News Update
Meme Update
Korean Entertainment News
Japan News Update
Bagikan Berita Ini
0 Response to "Should You Be Pleased About The CEO Pay At CTI BioPharma Corp.'s (NASDAQ:CTIC) - Yahoo Finance"
Post a Comment